Scarica l'app Stockscreener
8.55
0.71%
0.06
Precedente Chiudi:
$8.49
Aprire:
$8.335
Volume 24 ore:
11,904
Relative Volume:
0.64
Capitalizzazione di mercato:
$34.62M
Reddito:
$7.44M
Utile/perdita netta:
$-56.57M
Rapporto P/E:
0.3113
EPS:
27.467
Flusso di cassa netto:
$-21.40M
1 W Prestazione:
+6.61%
1M Prestazione:
+23.55%
6M Prestazione:
+23.55%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$8.335
$8.67
Intervallo di 1 settimana:
$7.595
$8.67
Portata 52W:
$6.32
$9.58
Kyntra Bio Inc Stock (KYNB) Company Profile
Nome
Kyntra Bio Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO
Compare KYNB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYNB
Kyntra Bio Inc
|
8.55 | 29.64M | 7.44M | -56.57M | -21.40M | 27.47 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyntra Bio Inc Stock (KYNB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
Mostra tutto
Kyntra Bio Inc Borsa (KYNB) Ultime notizie
Enterprise value to revenue forward of Kyntra Bio, Inc. – BX:KYNB - TradingView
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript - AOL.com
Kyntra Bio, Inc.Common Stock (Nasdaq:KYNB) Stock Quote - FinancialContent
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - Kalkine
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advanc - GuruFocus
Kyntra Bio, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-08-16 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackSector Neutral Pair - vinanet.vn
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc Q2 Net Income From Cont Ops US - moomoo.com
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - aol.com
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - Benzinga
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - Quiver Quantitative
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn - Stock Titan
Kyntra Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kyntra Bio Targets Late-2026 Milestones for Cancer and Anemia Drugs - Stock Titan
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
KYNB Q1 2026 Earnings: EPS Miss Deepens as Losses Exceed ExpectationsRevenue Estimate Trend - vinanet.vn
Kyntra Bio, Inc. expected to post a loss of $3.18 a shareEarnings Preview - TradingView
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on August 13 - 富途牛牛
KYNB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnGeographic Revenue Trends - vinanet.vn
KYNB Q2'26 Earnings: EPS estimate is (3.18) USD - TradingView
Kyntra Bio to Report Second Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio to host a live Q&A after Aug. 13 results - Stock Titan
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
KYNB Q2'26 Earnings: revenue estimate is 2.09M USD - TradingView
Kyntra Bio Inc. (KYNB) Edges Lower by 0.88% to $6.73 as Shares Consolidate Between Key Support and ResistanceFibonacci Entry Signals - dars.gov.et
Kyntra Bio (KYNB) Holds Near $6.78 as Biotech Sentiment Remains CautiousSupport Level Bounce - vinanet.vn
Kyntra Bio (KYNB) Holds Steady at $6.79 as Consolidation Builds Toward Key $7.13 TestLinear Regression - vinanet.vn
Kyntra Bio Inc. (KYNB) Holds Steady at $7.0 as Traders Eye Key LevelsRegression Channel - dars.gov.et
Kyntra Bio Inc. (KYNB) Gains 1.56% as Stock Approaches Key ResistanceBullish Sentiment - dars.gov.et
Kyntra Bio, Inc. Revenue Breakdown – NASDAQ:KYNB - TradingView
Kyntra Bio, Inc. (KYNB) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Biotech Faces R&D Cost PressureLong-Term Guidance - dars.gov.et
Kyntra Bio, Inc. (KYNB) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
KYNB Stock | Kyntra Bio, Inc. Price, Quote, News & Analysis - TipRanks
Kyntra Bio Inc Azioni (KYNB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kyntra Bio Inc Azioni (KYNB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):